A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 μg ethinylestradiol and either 150 μg desogestrel or 75 μg gestodene

Serfaty, D.; Vree, M. L.

doi:10.3109/13625189809167251

Cited by 31 publications

(27 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(1)(2)(3)(4)(5) But these oral contraceptives have some unavoidable disadvantages like first-pass metabolism, large fluctuations in serum hormone levels and poor compliance in some users (6)(7)(8) for which non-oral hormonal methods have been tried with their own drawbacks. (9,10) One of the advances in the contraceptive field has been the development of combined contraceptive vaginal rings (CCVRs).…”

Section: Introductionmentioning

confidence: 99%

To Study the Acceptability and Efficacy of Combined Contraceptive Vaginal Ring Amidst Indian Women

Dam¹,

Paul²,

Banerjee³

et al. 2015

jemds

View full text Add to dashboard Cite

OBJECTIVES:To study the efficacy, and acceptability and reasons for discontinuity of CCVRs in Indian women along with cycle control, safety aspects, local and systemic adverse effects, chances of spontaneous expulsion and partner compliance. METHODS: This interventional longitudinal study included 45 married women aged between 18-45 years seeking reversible means of contraception but with no history of usage of any form of hormonal contraceptives in the previous 6 months. The outcome variables were measured in terms of contraceptive efficacy, cycle regularity, systemic effects on blood pressure, liver function, body weight, lipid parameters and blood sugar along with local effect on cervix and vagina. Patient compliance, acceptability and spouse compliance was also measured by questionnaires. RESULTS: In this study there were no unwanted pregnancies in women amongst 117 exposed cycles. The incidence of intended bleeding pattern was 95%, the effect of CCVR on liver function, blood pressure, etc. was not clinically relevant. It was not associated with an increased risk of cervical or vaginal abnormalities, 96% women were satisfied with the ring usage and 97% would recommend it to others, 70% of women and 82% of their partners never/ rarely felt the ring during intercourse. CONCLUSION: From the present study, it can be concluded that CCVR is an effective contraceptive with good cycle control, minimal systemic or local adverse effects along with low incidence of spontaneous expulsion and higher level of user and partner acceptability.

show abstract

Section: Introductionmentioning

confidence: 99%

To Study the Acceptability and Efficacy of Combined Contraceptive Vaginal Ring Amidst Indian Women

Dam¹,

Paul²,

Banerjee³

et al. 2015

jemds

View full text Add to dashboard Cite

show abstract

“…The differences in cycle control and tolerability observed between starters and switchers were probably due to an already greater adaptation of switchers to the metabolism of the exogenous hormones contained in the study drug than those who were new to oral contraceptives, which enabled them rapidly to experience more regular cycles. Similar differences in cycle control between starters and switchers have been observed with monophasic oral contraceptives containing 20 µg ethinylestradiol with either desogestrel or gestodene 19 .…”

mentioning

confidence: 54%

“…As such, it does not counteract the estrogen-induced effects on lipid metabolism and sex hormone binding globulin, in contrast to the relatively more androgenic progestogen levonorgestrel 13 . Widely used monophasic combined oral contraceptives containing 20 µg or 30 µg ethinylestradiol, in combination with 150 µg desogestrel, have excellent efficacy, safety and cycle control [14][15][16][17][18][19] . Furthermore, these preparations are associated with a low incidence of subjective side-effects and have well-balanced effects on metabolism that are attributable to desogestrel.…”

mentioning

confidence: 99%

Multicenter study of the efficacy, cycle control and tolerability of a phasic desogestrel-containing oral contraceptive

Ferguson¹,

Vree²,

Wilpshaar³

et al. 2000

The European Journal of Contraception & Reproductive Health

Self Cite

View full text Add to dashboard Cite

show abstract

“…Suppression of ovulation has also been achieved by various other methods including oral contraceptives [52][53][54] and estradiol implants. 55 In general, oral contraceptives (especially new, lower-dose formulations) have not been carefully studied in comparably large, welldesigned trials.…”

Section: Anovulatory Treatments and Gonadal Steroidsmentioning

confidence: 99%

Premenstrual Dysphoric Disorder

Freeman

Sondheimer²

2003

Prim. Care Companion CNS Disord.

View full text Add to dashboard Cite

Articles are selected for CME credit designation on the basis of our assessment of the needs of readers of The Primary Care Companion, with the purpose of providing readers with a curriculum of CME articles on a variety of topics throughout each volume. There are no prerequisites for participation in this CME activity.To obtain credit, please study the designated article and complete the Posttest. Accreditation StatementPhysicians Postgraduate Press, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit DesignationPhysicians Postgraduate Press, Inc. designates this educational activity for up to 1 Category 1 credit toward the American Medical Association Physician's Recognition Award. Each participant should claim only those credits that he/she actually spent in the educational activity. Date of Original Release/ReviewThis educational activity is eligible for CME credit through April 30, 2004. The latest review of this material was January 2003. Educational ObjectivesAfter studying the article by Freeman and Sondheimer, the participant will be able to:• Discuss the epidemiology, clinical presentation, neurobiology, and treatment of premenstrual dysphoric disorder.This pretest is designed to facilitate your study of the material. Premenstrual dysphoric disorder (PMDD) represents the more severe and disabling end of the spectrum of premenstrual syndrome and occurs in an estimated 2% to 9% of menstruating women. The most frequent PMDD symptoms among women seeking treatment consist of anger/ irritability, anxiety/tension, feeling tired or lethargic, mood swings, feeling sad or depressed, and increased interpersonal conflicts. Women who develop PMDD appear to have serotonergic dysregulation that may be triggered by cyclic changes in gonadal steroids. The marked increase in the number of well-designed placebocontrolled studies in the past decade has established several selective serotonin reuptakeinhibiting antidepressants as effective first-line treatments for this disorder. Both continuous dosing and intermittent luteal dosing strategies lead to rapid improvement in symptoms and functioning. The present article provides a brief review of current information on the epidemiology, clinical presentation, neurobiology, and treatment of PMDD. Premenstrual dysphoric disorder is

show abstract

A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 μg ethinylestradiol and either 150 μg desogestrel or 75 μg gestodene

Abstract: Ultra low-dose oral contraceptives containing desogestrel or gestodene offer equivalent, good cycle control and improvements in dysmenorrhea and premenstrual syndrome and have similar, excellent tolerability profiles.

Cited by 31 publications

References 8 publications

To Study the Acceptability and Efficacy of Combined Contraceptive Vaginal Ring Amidst Indian Women

To Study the Acceptability and Efficacy of Combined Contraceptive Vaginal Ring Amidst Indian Women

Multicenter study of the efficacy, cycle control and tolerability of a phasic desogestrel-containing oral contraceptive

Premenstrual Dysphoric Disorder

Contact Info

Product

Resources

About